

according to Regulation (EC) No. 1907/2006

Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22206-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014	
SECTION	1: Identification of	the substance/mix	ture and of the company/undertaking	
1.1 Produc	t identifier			
Trade	name	: Ganirelix Formu	lation	
1.2 Relevant identified uses of the substance or mixture and uses advised against				
0000	f the Sub- e/Mixture	: Pharmaceutical		

1.3 Details of the supplier of the safety data sheet

Company	:	Organon & Co. Shotton Lane NE23 3JU Cramlington NU - Great Britain
Telephone	:	44 1 670 59 30 00
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

2.2

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATIC Reproductive toxicity, Catego			2/2008) H360Fd: May damage fertility. Suspected of dam- aging the unborn child.
Specific target organ toxicity - repeated exposure, Category 1			H372: Causes damage to organs through pro- longed or repeated exposure.
Label elements			
Labelling (REGULATION (EC) No 1272/200 Hazard pictograms :			8)
Signal word	:	Danger	
Hazard statements	:	H360Fd the unborn H372 Ca peated exp	uses damage to organs through prolonged or re-

Precautionary statements

P201 Obtain special instructions before use.

: Prevention:

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22206-00018	Date of first issue: 15.10.2014

P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label: Ganirelix

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		. ,
	Registration number		
Ganirelix	124904-93-4	Repr. 1B; H360Fd	>= 0.01 - < 0.1
		STOT RE 1; H372	
		(Bone marrow, Liver,	
		Adrenal gland,	
		spleen, Ovary)	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures


General advice	vice ir	case of accident or if you feel unwell, seek medical ad- nmediately. symptoms persist or in all cases of doubt seek medical e.
Protection of first-aiders	and u	Aid responders should pay attention to self-protection, se the recommended personal protective equipment the potential for exposure exists (see section 8).
If inhaled		led, remove to fresh air. edical attention.
In case of skin contact	: In cas	e of contact, immediately flush skin with soap and plenty

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

4.5	Revision Date: 09.04.2021	-	S Number: 206-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014		
			Get medical atte Wash clothing be			
In cas	se of eye contact	:		vater as a precaution. ntion if irritation develops and persists.		
lf swa	If swallowed		: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.			
4.2 Most i	mportant symptoms a	nd e	ffects, both acut	e and delayed		
Risks	i	:	child.	ility. Suspected of damaging the unborn to organs through prolonged or repeated		
			exposure.	to organs through proionged of repeated		
4.3 Indica	tion of any immediate	mer	ical attention an	d special treatment needed		
Treat	•	:		ically and supportively.		
Suita	Juishing media ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (Dry chemical			
	itable extinguishing	:	None known.			
media	a					
		the		ixture		
5.2 Specia	al hazards arising from ific hazards during fire-	the :	substance or m	xture bustion products may be a hazard to health.		
5.2 Speci Spec fightir	al hazards arising from ific hazards during fire-	the :	substance or m Exposure to com			
5.2 Speci a Spec fightir Haza ucts	al hazards arising from ific hazards during fire- ng	:	substance or m Exposure to com	bustion products may be a hazard to health.		
 5.2 Special Spect fightin Haza ucts 5.3 Advice Spec 	al hazards arising from ific hazards during fire- ng rdous combustion prod-	:	substance or m Exposure to com No hazardous co	bustion products may be a hazard to health.		





Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22206-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014		
		Evacuate a	rea.		
SECTION	N 6: Accidental rele	ase measures			
6.1 Perso	nal precautions, prot	ective equipment	and emergency procedures		
Personal precautions		Follow safe	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).		
6.2 Enviro	onmental precautions	i			
Environmental precautions		Prevent furt Prevent spr barriers). Retain and Local autho	 Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. 		
6.3 Metho	ods and material for c	ontainment and c	leaning up		
Methods for cleaning up		: Soak up wit For large sp ment to kee be pumped Clean up re bent.	h inert absorbent material. ills, provide dyking or other appropriate contain- p material from spreading. If dyked material can store recovered material in appropriate container. maining materials from spill with suitable absor-		
		posal of this employed ir mine which Sections 13	ional regulations may apply to releases and dis- material, as well as those materials and items the cleanup of releases. You will need to deter- regulations are applicable. and 15 of this SDS provide information regarding I or national requirements.		
6.4 Refere	ence to other section	6			
See section	ons: 7, 8, 11, 12 and 13	B.			

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION sectior	1.
Local/Total ventilation	If sufficient ventilation is unavailable, use with lo ventilation.	al exhaust
Advice on safe handling	Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygie practice, based on the results of the workplace of sessment	

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22206-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014		
Hygiene measures		Do not eat, of Take care to environment If exposure flushing syst place. When nated clothin The effective engineering appropriate industrial hy	Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.		
7.2 Condi	itions for safe storage,	including any in	compatibilities		
	irements for storage and containers		perly labelled containers. Store locked up. Keep d. Store in accordance with the particular national		
Advid	ce on common storage	: Do not store Strong oxidi Organic per Explosives Gases			
-	fic end use(s) ific use(s)	: No data ava	ilable		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ganirelix	124904-93- 4	TWA	0.2 μg/m3 (OEB 5)	Internal
		Wipe limit	2 µg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Numbe 22206-00018			
Eye protection Hand protection		If the wor mists or a Wear a fa potential	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.		
Tianc					
Μ	Material		I-resistant gloves		
Remarks Skin and body protection Respiratory protection		: Work uni Additiona task bein posable s Use appr contamin	double gloving. form or laboratory coat. Il body garments should be used based upon the g performed (e.g., sleevelets, apron, gauntlets, dis- suits) to avoid exposed skin surfaces. opriate degowning techniques to remove potentially ated clothing. nal respiratory protective equipment normally re-		
		quired.			

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	Aqueous solution No data available No data available No data available
рН	:	5
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	100 °C
range Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	23 hPa (20 °C)
Relative vapour density	:	No data available
Relative density	:	1

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22206-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014
W Partit octan Auto- Deco Visco Visco	pility(ies) ater solubility ion coefficient: n- iol/water ignition temperature mposition temperature sity scosity, kinematic psive properties zing properties	 completely mi No data availa No texplosive The substance 	able able able
Moleo	information cular weight cle size	: No data availa : No data availa	

SECTION 10: Stability and reactivity

10.1 Reactivity	
Not classified as a reactivity hazar	d.
10.2 Chemical stability	
Stable under normal conditions.	
10.3 Possibility of hazardous reaction	ns
Hazardous reactions :	Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid :	None known.
10.5 Incompatible materials	
Materials to avoid :	Oxidizing agents
10.6 Hazardous decomposition prod	ucts
No hazardous decomposition proc	lucts are known.
SECTION 11: Toxicological inform	nation

11.1 Information on toxicological effects

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22206-00018	Date of first issue: 15.10.2014

Acute toxicity

Not classified based on available information.

Components:

Ganirelix:

Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg administration)

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Species	:	Rabbit
Method	:	Draize Test
Result	:	Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ganirelix:

Test Type	:	Maximisation Test
Species	:	Guinea pig
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ganirelix:

Genotoxicity in vitro	:	Test Type: reverse mutation assay Test system: Salmonella typhimurium Result: negative
-----------------------	---	--

Test Type: reverse mutation assay Test system: Escherichia coli Result: negative

Test Type: in vitro assay Test system: Chinese hamster ovary cells Result: negative

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Versi 4.5	on	Revision Date: 09.04.2021		S Number: 206-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014
(Genoto	xicity in vivo	:	Test Type: In vivo Species: Mouse Application Route Result: negative	micronucleus test : Intravenous
	Germ o sessme	ell mutagenicity- As- ent	:	Weight of evidenc cell mutagen.	e does not support classification as a germ
l	Not cla Reproc	ogenicity ssified based on availa ductive toxicity image fertility. Suspect			born child.
	•	onents:		0 0	
	Ganire Effects	lix: on fertility	:	Species: Rat Application Route Duration of Single Fertility: LOAEL: 0 Result: Effects on Test Type: Fertility Species: Rat, fem Application Route Duration of Single Fertility: LOAEL: 1 Result: No effects Test Type: Fertility Species: Monkey Application Route	a Treatment: 13 Weeks 0.1 μg/kg fertility y/early embryonic development ale : Subcutaneous a Treatment: 8 Weeks 10 μg/kg on mating performance, Effects on fertility y
	Effects ment	on foetal develop-	:	Result: Effects on Test Type: Embry Species: Rat, fem Application Route Embryo-foetal tox Result: Embryo-fo Test Type: Embry Species: Rabbit, f Application Route Embryo-foetal tox	fertility o-foetal development ale : Subcutaneous icity: LOAEL: 10 μg/kg betal toxicity o-foetal development emale : Subcutaneous icity: LOAEL: 30 μg/kg
	Reproc sessme	luctive toxicity - As- ent	:	ity, based on anim	adverse effects on sexual function and fertil- nal experiments., Some evidence of adverse oment, based on animal experiments.

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22206-00018	Date of first issue: 15.10.2014

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Ganirelix:

Exposure routes	: Ingestion
Target Organs	: Bone marrow, Liver, Adrenal gland, spleen, Ovary
Assessment	: Causes damage to organs through prolonged or repeated
	exposure.

Repeated dose toxicity

Components:

Ganirelix:

••	Rat 0.02 mg/kg 2 mg/kg Subcutaneous 6 Months Bone marrow
Exposure time	Mouse, female 0.3 mg/kg Subcutaneous 3 Months Liver, Adrenal gland, spleen, Ovary
TT	Mouse, male 3 mg/kg Subcutaneous 3 Months Liver, Adrenal gland, spleen
	Monkey 2.5 mg/kg Subcutaneous 6 Months No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

:

Experience with human exposure

Components:

Ganirelix:

Inhalation


Symptoms: The most common side effects are:, vaginal bleeding, Headache, Abdominal pain, Nausea, ectopic preg-

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22206-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014
		nancy, miscari	iage
SECTION	N 12: Ecological infor	mation	
12.1 Toxi	city		
<u>Com</u>	ponents:		
Gani	relix:		
Ecot	oxicology Assessment		
Acute	e aquatic toxicity	: No data availa	ble
Chro	nic aquatic toxicity	: No data availa	ble
	istence and degradabil i ata available	ty	
	ccumulative potential ata available		
	i lity in soil ata available		
12.5 Resu	Its of PBT and vPvB as	sessment	
<u>Prod</u>	<u>uct:</u>		
Asse	ssment	to be either pe	e/mixture contains no components considered rsistent, bioaccumulative and toxic (PBT), or and very bioaccumulative (vPvB) at levels of
12.6 Othe	r adverse effects		
Prod	uct:		
Endo tial	crine disrupting poten-	ered to have e REACH Article	/mixture does not contain components consid- ndocrine disrupting properties according to 57(f) or Commission Delegated regulation 0 or Commission Regulation (EU) 2018/605 at or higher.
SECTION 13: Disposal considerations			
13.1 Waste treatment methods			
Produ	uct	According to the are not produce Waste codes so discussion with	accordance with local regulations. The European Waste Catalogue, Waste Codes t specific, but application specific. Thould be assigned by the user, preferably in the waste disposal authorities.
Conta	aminated packaging	dling site for re	ers should be taken to an approved waste han- cycling or disposal. e specified: Dispose of as unused product.





Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22206-00018	Date of first issue: 15.10.2014

SECTION 14: Transport information

14.1 UN number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 3 Not applicable
REACH - List of substances subject to authorisation	:	Not applicable
(Annex XIV) Regulation (EC) No 1005/2009 on substances that de-	:	Not applicable
plete the ozone layer Regulation (EU) 2019/1021 on persistent organic pollu-		Not applicable
tants (recast)	•	
Regulation (EC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import	:	Not applicable
of dangerous chemicals		
Seveso III: Directive 2012/18/EU of the European Parlian	nent	and of the Council on the control of

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

not determined

AICS :

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 22206-00018	Date of last issue: 16.10.2020 Date of first issue: 15.10.2014		
DS	SL	: not determined	t.		
IEC	CSC	: not determined	ł		
15.2 Chemical safety assessment A Chemical Safety Assessment has not been carried out.					
SECTION 16: Other information					
6			Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.		
Fu	II text of H-Statements				
H3	60Fd	: May damage f child.	ertility. Suspected of damaging the unborn		
H3	72	: Causes damag	Causes damage to organs through prolonged or repeated exposure if swallowed.		
Fu	Full text of other abbreviations				
Re ST	pr. OT RE	: Reproductive t : Specific target	oxicity organ toxicity - repeated exposure		

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -

according to Regulation (EC) No. 1907/2006



Ganirelix Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 16.10.2020
4.5	09.04.2021	22206-00018	Date of first issue: 15.10.2014

Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

Classification of the mixture:		Classification procedure:
Repr. 1B	H360Fd	Calculation method
STOT RE 1	H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN